SAISENTONG


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H4CuN6S4
Molecular Weight	339.93
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Assay Description	Organism	Bioactivity
Antibacterial activity against Ralstonia solanacearum assessed as growth inhibition at 500 ug/ml by turbidometer test (beneficial crop tobacco plant)	Ralstonia solanacearum	100.0 %
Antibacterial activity against Ralstonia solanacearum assessed as growth inhibition at 200 ug/ml by turbidometer test (beneficial crop tobacco plant)	Ralstonia solanacearum	100.0 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as plant morbidity at 500 ug/ml measured after 7 days of spraying under green house conditions	Ralstonia solanacearum	6.7 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as disease index at 500 ug/ml measured after 7 days of spraying under green house conditions	Ralstonia solanacearum	6.7 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as control efficacy at 500 ug/ml measured after 7 days of spraying under green house conditions	Ralstonia solanacearum	92.7 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as plant morbidity at 500 ug/ml measured after 14 days of spraying under green house conditions	Ralstonia solanacearum	73.3 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as disease index at 500 ug/ml measured after 14 days of spraying under green house conditions	Ralstonia solanacearum	40.0 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as control efficacy at 500 ug/ml measured after 14 days of spraying under green house conditions	Ralstonia solanacearum	59.3 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as plant morbidity at 500 ug/ml measured after 21 days of spraying under green house conditions	Ralstonia solanacearum	100.0 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as disease index at 500 ug/ml measured after 21 days of spraying under green house conditions	Ralstonia solanacearum	78.3 %
Antibacterial activity against Ralstonia solanacearum in tobacco plant assessed as control efficacy at 500 ug/ml measured after 21 days of spraying under green house conditions	Ralstonia solanacearum	21.7 %
Antibacterial activity against Ralstonia solanacearum in tobacco field assessed as inhibition of disease at 540 g/ha measured after 7 days of spraying	Ralstonia solanacearum	61.2 %
Antibacterial activity against Ralstonia solanacearum in tobacco field assessed as inhibition of disease at 540 g/ha measured after 14 days of spraying	Ralstonia solanacearum	71.1 %
Antibacterial activity against Ralstonia solanacearum in tobacco field assessed as inhibition of disease at 540 g/ha measured after 21 days of spraying	Ralstonia solanacearum	67.3 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2228965

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).